WithdrawnPhase 3NCT05432960

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Studying Adult-onset Still disease

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: R-Pharm International, LLC
Principal Investigator: Mikhail Samsonov
Chief Medical Officer, R-Pharm
Intervention: RPH-104(biological)
Eligibility: 18 years · All sexes
Timeline: 2023 – 2025

Study locations (4)

Research Institute of Rheumatology. V.A. Nasonova, Moscow, Russia
Clinic of Nephrology, Internal and Occupational Diseases. EAT. Tareeva, University Clinical Hospital No. 3, Moscow, Russia
State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology, Saint Petersburg, Russia
FGBU "National Medical Research Center named after V.A. Almazov", Ministry of Health of the Russian Federation, Department of Rheumatology, Saint Petersburg, Russia

Collaborators

Exacte Labs LLC · Ministry of Health, Russian Federation · Scientific Center EFiS LLC · Data Management 365

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05432960 on ClinicalTrials.gov

Other trials for Adult-onset Still disease

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset Still disease →

← Back to all trials